RESUMEN
A specific and reliable HPLC-MS/MS method was developed and validated for the simultaneous determination of 1-ß-d-Arabinofuranosylcytosine (ara-C), 1-ß-d-Arabinofuranosyluracil (ara-U) and 1-ß-d-Arabinofuranosylcytosine triphosphate (ara-CTP) in the leukemic cells for the first time. The analytes were separated on a C18 column (100mm×2.1mm, 1.8µm) and a triple-quadrupole mass spectrometry equipped with an electrospray ionization (ESI) source was used for detection. The ion-pairing reagent, NFPA, was added to the mobile phase to retain the analytes in the column. The cell homogenates sample was prepared by the simple protein precipitation. The calibration curves were linear over a concentration range of 3.45-3450.0ng/mL for ara-C, 1.12-1120.0ng/mL for ara-U and 4.13-4130.0ng/mL for ara-CTP. The intra-day and inter-day precision was less than 15% and the relative error (RE) were all within ±15%. The validated method was successfully applied to assess the disposition characteristics of ara-C and support cell pharmacokinetics after the patients with leukemia were intravenously infused with SDAC and HiDAC. The result of the present study would provide the valuable information for the ara-C therapy.
Asunto(s)
Antimetabolitos Antineoplásicos/farmacocinética , Trifosfato de Arabinofuranosil Citosina/farmacocinética , Arabinofuranosil Uracilo/farmacocinética , Citarabina/farmacocinética , Adulto , Antimetabolitos Antineoplásicos/análisis , Antimetabolitos Antineoplásicos/sangre , Trifosfato de Arabinofuranosil Citosina/análisis , Trifosfato de Arabinofuranosil Citosina/sangre , Arabinofuranosil Uracilo/análisis , Arabinofuranosil Uracilo/sangre , Línea Celular Tumoral , Cromatografía Líquida de Alta Presión/métodos , Citarabina/análisis , Citarabina/sangre , Humanos , Límite de Detección , Persona de Mediana Edad , Espectrometría de Masas en Tándem/métodos , Adulto JovenRESUMEN
A novel whole cell bacterial biosensor, which emits light in response to the active metabolite of cytosine arabinoside (ara-C, cytarabine), ara-CTP, has been investigated and verified. The biosensor has been formulated as an ex vivo assay, designed for peripheral blood or bone marrow cells, which can produce a clinical result within a working day. The nucleoside analogue ara-C is a key agent for treatment of acute myeloid leukaemia (AML); treatment decisions are made rapidly with AML, patients often receiving same-day commencement of chemotherapy. Currently no rapid predictive test is available to select appropriate therapy for patients prior to treatment. Experiments were designed to determine optimal assay conditions using leukaemic cell lines. We observed a significant increase (~15 fold) in bioluminescence signal compared to control after 8-h incubation of the biosensor with ara-C. This corresponded to a >2-log increase in light output per bacterial cell. Interestingly, bioluminescence conferred a survival advantage to the bacteria following ara-C treatment. The assay is sensitive (lower limit of quantitation of 0.05 µM), selective, accurate (≤ 15% RE) and precise (≤ 15% coefficient of variation) over a linear concentration range of ara-CTP (0.05-0.5 µM), and detection is independent of reaction volume. Recovery of added standard was tested using ex vivo patient leukaemic cells (n=5). Stability studies on lyophilized bacterial biosensor were performed to ensure maintenance of performance over 12 months. The biosensor assay could be invaluable to the clinician, assisting with treatment selection, and potentially mitigating the risks of resistance and toxicity observed with this drug.
Asunto(s)
Trifosfato de Arabinofuranosil Citosina/aislamiento & purificación , Técnicas Biosensibles , Citarabina/aislamiento & purificación , Leucemia Mieloide Aguda/sangre , Trifosfato de Arabinofuranosil Citosina/sangre , Biomarcadores de Tumor/sangre , Humanos , Leucemia Mieloide Aguda/patología , Límite de Detección , Mediciones LuminiscentesRESUMEN
Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. These characteristics lead to poor efficacy, high toxicity, and a drug class associated with an unacceptable therapeutic index. Cyclic 1-aryl-1,3-propanyl phosphate prodrugs selectively release the monophosphate of a nucleoside (NMP) into CYP3A4-expressing cells, such as hepatocytes, while leaving the prodrug intact in plasma and extrahepatic tissues. This prodrug strategy was applied to the monophosphate of the well-known cytotoxic nucleoside cytosine-1-beta-D-arabinofuranoside (cytarabine, araC). Compound 19S (MB07133), in mice, achieves good liver targeting compared to araC, generating >19-fold higher cytarabine triphosphate (araCTP) levels in the liver than levels of araC in the plasma and >12-fold higher araCTP levels in the liver than in the bone marrow, representing a >120-fold and >28-fold improvement, respectively, over araC administration.
Asunto(s)
Antineoplásicos/farmacología , Arabinonucleotidos/síntesis química , Carcinoma Hepatocelular/tratamiento farmacológico , Citidina Monofosfato/análogos & derivados , Hígado/efectos de los fármacos , Profármacos/farmacología , Animales , Antineoplásicos/síntesis química , Antineoplásicos/farmacocinética , Trifosfato de Arabinofuranosil Citosina/sangre , Arabinonucleotidos/farmacocinética , Arabinonucleotidos/farmacología , Médula Ósea/efectos de los fármacos , Médula Ósea/metabolismo , Cromatografía Líquida de Alta Presión , Citidina Monofosfato/síntesis química , Citidina Monofosfato/farmacocinética , Citidina Monofosfato/farmacología , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Neoplasias Hepáticas/tratamiento farmacológico , Masculino , Ratones , Profármacos/síntesis química , Profármacos/farmacocinética , Ratas , Distribución TisularRESUMEN
The purpose of this study was to develop an analytical method for the determination of 2'-fluoro-5-methyl-beta-l-arabinofuranosyl uracil triphosphate (L-FMAU-TP) in human peripheral blood mononuclear cells (PBMCs), and its application in the determination of cellular levels of L-FMAU-TP in PBMCs isolated from patients treated with 2'-fluoro-5-methyl-beta-l-arabinofuranosyl uracil (L-FMAU). An ion-pairing liquid chromatography (IPC) method, coupled with negative ion electrospray ionization tandem mass spectrometry (ESI-MS/MS), was developed for the accurate and repeatable detection of L-FMAU-TP, with a limit of detection of 1.6 pmol/10 cells. The calibration curve for L-FMAU-TP was linear over the concentration range 1.6 to 80 pmol/10(6) cells. The intra- and inter-day precision was lower than 11.2%, and the accuracy was between 97.1 and 106.9%. When applied to the determination of L-FMAU-TP in PBMCs isolated from HBV-infected patients undergoing L-FMAU treatment, the levels reached a steady state concentration 4 weeks after daily single oral administration of 20 mg L-FMAU, and these levels were maintained for up to 12 weeks, but then decreased 12 weeks after drug cessation. The terminal half-life of L-FMAU-TP in PBMCs after drug cessation was estimated to be 15.6 days.
Asunto(s)
Trifosfato de Arabinofuranosil Citosina/análogos & derivados , Cromatografía Líquida de Alta Presión/métodos , Hepatitis B/sangre , Adulto , Antivirales/uso terapéutico , Trifosfato de Arabinofuranosil Citosina/sangre , Trifosfato de Arabinofuranosil Citosina/farmacocinética , Arabinofuranosil Uracilo/análogos & derivados , Arabinofuranosil Uracilo/uso terapéutico , Semivida , Hepatitis B/tratamiento farmacológico , Humanos , Espectrometría de Masas/métodos , Persona de Mediana Edad , Reproducibilidad de los ResultadosRESUMEN
N(4)-Behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC), a prodrug of 1-beta-D-arabinofuranosylcytosine, is used effectively for the treatment of leukemia in Japan. BHAC therapy may be more effective if it is delivered in conjunction with monitoring of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP), the intracellular active metabolite of ara-C derived from BHAC. However, previous monitoring methods for ara-CTP were insufficiently sensitive. Here, using our new sensitive method, we evaluated the ara-CTP pharmacokinetics in relation to the therapeutic response in 11 acute myelogenous leukemia patients who received a 2-h infusion of BHAC (70 mg / m(2)) in combination remission induction therapy. ara-CTP could be monitored at levels under 1 mM. BHAC maintained effective levels of plasma ara-C and intracellular ara-CTP for a longer time, even compared with historical values of high-dose ara-C. The area under the concentration-time curve of ara-CTP was significantly greater in the patients with complete remission than in the patients without response. This greater amount of ara-CTP was attributed to the higher ara-CTP concentrations achieved in the responding patients. There was no apparent difference of plasma ara-C pharmacokinetics between the two groups. Thus, for the first time, the ara-CTP pharmacokinetics was evaluated in relation to the therapeutic effect of BHAC, and the importance of ara-CTP was proven. Administration of optimal BHAC therapy may require monitoring of the ara-CTP pharmacokinetics in each individual patient.
Asunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Trifosfato de Arabinofuranosil Citosina/farmacocinética , Citarabina/análogos & derivados , Citarabina/uso terapéutico , Leucemia Mieloide/tratamiento farmacológico , Células Madre Neoplásicas/química , Profármacos/uso terapéutico , Enfermedad Aguda , Adulto , Anciano , Anciano de 80 o más Años , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/farmacocinética , Antimetabolitos Antineoplásicos/farmacología , Trifosfato de Arabinofuranosil Citosina/análisis , Trifosfato de Arabinofuranosil Citosina/sangre , Área Bajo la Curva , Biotransformación , Citarabina/administración & dosificación , Citarabina/sangre , Citarabina/farmacocinética , Citarabina/farmacología , Femenino , Humanos , Infusiones Intravenosas , Líquido Intracelular/química , Leucemia Mieloide/sangre , Masculino , Persona de Mediana Edad , Profármacos/administración & dosificación , Profármacos/farmacocinética , Profármacos/farmacología , Inducción de Remisión , Sensibilidad y Especificidad , Resultado del TratamientoRESUMEN
The increasing insights into the pharmacokinetics and the metabolism of arabinoside C (AraC) have improved the rationale for its application in leukemia therapy and have led to a pharmacologically directed design of antileukemic treatment. The current study aims at adding to this approach by detecting differences in the intracellular metabolism of AraC 5'-triphosphate (AraCTP) between leukemic and normal mononuclear blood cells. Measurements of intracellular AraCTP levels were complemented by determinations of plasma AraC and arabinoside uridine (AraU) concentrations and were performed in 26 patients with acute myeloid leukemia (AML) who were undergoing combination therapy, including high-dose (1.0 or 3.0 g/m2 x 2/day) AraC. Plasma AraC concentrations showed a linear relationship to the applied AraC dose but did not correlate with intracellular AraCTP levels. Substantial differences in AraCTP retention times were revealed, during 3-h infusions of either 1.0 or 3.0 g/m2 AraC in leukemic blasts from 10 patients with t1/2 values of 1.60-7.63 h (median, 2.42 h). In addition, AraCTP levels declined in only one patient by > 10% within the first hour after the end of therapy and remained constant or even increased up to 1.5-fold during a posttreatment period of 1-2.5 h in the other nine cases. In contrast, AraCTP retention times were relatively uniform in normal mononuclear blood cells from 11 patients, with t1/2 values of 3.34-5.29 h (median, 3.85 h). More importantly, AraCTP levels dropped by > 10% within the first hour after the end of the high-dose AraC infusion in eight of 11 cases. A posttherapeutic increase of > 10% was not observed in any patient. These differences in AraCTP pharmacokinetics between leukemic and normal blood cells provided the basis for a modified timing of AraC administration with the aim of selectively maintaining cytotoxic AraCTP levels in leukemic blasts while allowing an intermittent drop of AraCTP levels in normal cells. This modification may result in higher antileukemic activity without increasing the damaging effect on normal cells and may, thus, improve the therapeutic index for AraC.
Asunto(s)
Antimetabolitos Antineoplásicos/farmacocinética , Trifosfato de Arabinofuranosil Citosina/sangre , Arabinofuranosil Uracilo/sangre , Citarabina/farmacocinética , Leucemia Mieloide/sangre , Leucocitos Mononucleares/metabolismo , Enfermedad Aguda , Femenino , Humanos , Leucemia Mieloide/tratamiento farmacológico , MasculinoRESUMEN
A new sensitive method for the measurement of 1-beta-D-arabinofuranosyl-CTP (ara-CTP), an intracellular active metabolite of 1-beta-D-arabinofuranosylcytosine (ara-C), in human materials in vivo has been established. An acid-soluble fraction containing ara-CTP was extracted from blastic cells by ara-C treatment with trichloroacetic acid (final concentration, 0.3 M) neutralized with an equal volume of cold freon containing 0.5 M tri-n-octylamine. The ara-CTP fraction was separated from the acid -soluble fraction by high-performance liquid chromatography (TSK gel diethylaminoethyl-2 SW column) eluted with 0.05 M phosphate buffer (pH 6.9) and 20% acetonitrile. ara-CTP was lyophilized, dephosphorylated to ara-C by incubation with 10 units alkaline phosphatase for 12 h at 55 degrees C, and measured by RIA using anti-ara-C serum. Recovery through the whole procedure was 92%. In the human chronic myelogenous leukemia cell line K562, the intracellular ara-CTP levels produced when the cells were incubated with ara-c were assayed as above, and they showed a linear increase depending on Ara-C concentrations from 0.01 to 10 microns, demonstrating a very close correlation with the labeled ara CTP levels yielded by cells on incubation with radiolabeled ara-C (r2 = 0.99). The detection limit was 0.1 pmol/5 x 10(6) cells, and a sample amount of only 5 x 10(6) cells was enough for each assay. In the clinical applications, our method proved capable of detecting a wide concentration range of ara-CTP produced when patients were treated with ara-C or its derivatives from very low to intermediate doses. No radiolabeled drug was necessary. The method was very useful for in vivo pharmacodynamic studies of ara-C therapy.
Asunto(s)
Trifosfato de Arabinofuranosil Citosina/análisis , Fosfatasa Alcalina , Trifosfato de Arabinofuranosil Citosina/sangre , Crisis Blástica , Línea Celular , Cromatografía Líquida de Alta Presión/métodos , Cromatografía en Capa Delgada/métodos , Citarabina/metabolismo , Citarabina/uso terapéutico , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva , Leucemia Mieloide Aguda/sangre , Leucemia Mieloide Aguda/tratamiento farmacológico , Síndromes Mielodisplásicos/sangre , Síndromes Mielodisplásicos/tratamiento farmacológico , Radioinmunoensayo/métodos , Sensibilidad y Especificidad , Células Tumorales CultivadasRESUMEN
We hypothesized that the steady-state concentration of intracellular cytarabine 5'-triphosphate (ara-CTPss) in leukemia cells is proportional to the dose rate of cytarabine (ara-C) during continuous infusion. To evaluate this possibility, patients with acute myelogenous leukemia in relapse were treated with two sequential schedules of serially increasing ara-C dose rates over a total of 36 hours. Schedule I consisted of serial infusions of 250, 500, and 750 mg/m2 each over 12 hours. Subsequently, patients entered on schedule II received 500, 1,000, and 1,500 mg/m2 serially, each over 12 hours. Steady-state levels of ara-CTP were achieved within four hours after beginning ara-C infusion and, in separate studies of a single ara-C dose rate, were shown to be maintained beyond 36 hours. Four patients treated with schedule I and two patients treated with schedule II showed a linear dose rate-dependent increase-of ara-CTPss at all three dose rates. The cells of one patient on schedule I and two patients on schedule II had a dose rate-dependent ara-CTPss increase only over the first two dose levels, while no increase or lower ara-CTPss was observed at the third dose rate. The ara-CTPss of one patient on schedule II did not change. These results suggest that there is a proportionality between the continuous infusion dose rate of ara-C and the ara-CTPss in circulating leukemia cells within the dose range of 250 to 1,000 mg/m2 over 12 hours. This opens the possibility that pharmacologic determinations may be used to redirect the ara-C dose rate to achieve a desired ara-CTPss level in leukemia blasts during therapy.
Asunto(s)
Citarabina/administración & dosificación , Leucemia Mieloide Aguda/tratamiento farmacológico , Adulto , Trifosfato de Arabinofuranosil Citosina/sangre , Citarabina/farmacocinética , Citarabina/uso terapéutico , Esquema de Medicación , Femenino , Humanos , Leucemia Mieloide Aguda/metabolismo , Masculino , Persona de Mediana EdadRESUMEN
The pharmacodynamic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) in patient plasma and its active anabolite 1-beta-D-arabinofuranosylcytosine-5-triphosphate (ara-CTP) in circulating and bone marrow blast cells were studied in 20 pediatric patients with acute leukemia. ara-C (3 g/m2) was administered as a short-term infusion over 3 h every 12 h for a total of eight doses. The peak plasma concentration of ara-C ranged from 0.02 to 5.6 microM after the first dose of ara-C. The area under the concentration-time curve (AUC) of ara-C in plasma ranged from 302 to 20,298 microMh after the first dose of ara-C. The half-life of elimination (t1/2,el) of ara-C from plasma was 2.4 +/- 1.5 h in three patients with acute nonlymphoblastic leukemia (ANLL) and 4.78 +/- 4.1 h in 9 patients with acute lymphoblastic leukemia (ALL). The intracellular peak concentration of ara-CTP in circulating blast cells averaged 432.2 +/- 14.5 microM and 544.3 +/- 330 microM in patients with ANLL and ALL, respectively. The elimination kinetics of ara-CTP was monoexponential with t1/2,el of 3.30 +/- 0.8 h and 6.9 +/- 2.8 h in patients with ANLL and ALL. DNA synthetic capacity (DSC) of the blast cells was inhibited to between 24 and 64% of control after the first dose of ara-C and it declined further to between 1 and 32% after four doses of ara-C. The AUC of ara-CTP in leukemic cells ranged from 1,073 to 14,751 microMh and it was not related to the AUC of ara-C in plasma. The pharmacodynamic parameters of ara-CTP in circulating blast cells were more homogeneous in patients with ANLL than in patients with ALL. Four of six patients (67%) with ANLL and six of 14 patients (43%) with ALL achieved either complete remission or partial remission with high dose ara-C. We conclude that treatment of pediatric patients with leukemia in relapse with high dose ara-C is tolerable and moderately successful. Inhibition of DSC is positively correlated with the probability of having zero nadir peripheral blast cells. In turn there is a trend for a zero nadir peripheral blast cell count to be related to achievement of a response to therapy. This latter result is consistent with the results of larger studies in adults with leukemia.
Asunto(s)
Citarabina/farmacocinética , Leucemia/tratamiento farmacológico , Trifosfato de Arabinofuranosil Citosina/sangre , Niño , Citarabina/administración & dosificación , Citarabina/efectos adversos , Semivida , Humanos , Leucemia/sangre , Leucemia Linfoide/sangre , Leucemia Linfoide/tratamiento farmacológico , Neutropenia/inducido químicamenteAsunto(s)
Amsacrina/administración & dosificación , Trifosfato de Arabinofuranosil Citosina/metabolismo , Arabinonucleotidos/metabolismo , Citarabina/administración & dosificación , Leucemia/tratamiento farmacológico , Trifosfato de Arabinofuranosil Citosina/sangre , Relación Dosis-Respuesta a Droga , Humanos , Leucemia/metabolismo , Tasa de Depuración MetabólicaRESUMEN
The pharmacokinetic values of 1-beta-D-arabinofuranosylcytosine (ara-C) in plasma and its active metabolite 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) in circulating blast cells were studied in 11 patients with acute leukemia. ara-C was administered as a 2-h infusion (3 g/m2) followed in 12 to 24 h by a continuous infusion for 4 days in 10 patients and for 7 days in one. A steady-state concentration of ara-C in plasma (94 +/- 32 microM) was reached by the end of the 2-h infusion. Its elimination was biphasic with an initial and terminal t1/2 of 0.44 +/- 0.10 h and 2.8 +/- 0.9 h, respectively. The accumulation of ara-CTP in leukemic cells was linear and continued for up to 2 h after the bolus infusion. ara-CTP elimination was monophasic with a median t1/2 of 3.4 h (range, 1.25 to 18.9 h). The disposition of ara-C and 1-beta-D-arabinofuranosyluracil during continuous infusion was linear with dose rate over the dose range of 70 to 3000 mg/m2/day. The area under the concentration versus time curve for ara-CTP in leukemic cells was not related to the dose infused, but rather appeared to be intrinsic to the cells of each individual. As a general finding, the pharmacokinetic values of ara-CTP in circulating blasts were more heterogeneous than those of ara-C in plasma. There were marked differences in the absolute concentrations of ara-C in plasma and ara-CTP in leukemic cells at different times after the bolus infusion and also during continuous infusion. No correlation was evident between the determinants of ara-C pharmacokinetic values and those of ara-CTP. Thus, it is concluded that the pharmacokinetics of ara-C in plasma cannot predict for the metabolism of ara-CTP in leukemic cells.
Asunto(s)
Trifosfato de Arabinofuranosil Citosina/sangre , Arabinonucleotidos/sangre , Citarabina/sangre , Leucemia/metabolismo , Citarabina/administración & dosificación , Humanos , Cinética , Leucemia/tratamiento farmacológicoRESUMEN
During a two-year experience treating patients with refractory acute leukemia with a fixed 12-hour schedule of high-dose ara-C, cellular ara-CTP pharmacodynamics were ascertained in circulating blasts of these patients. A strong correlation was found between achievement of complete remission and cellular ara-CTP levels. We therefore, attempted to improve the complete remission rate in patients with low ara-CTP levels by decreasing the intermittent ara-C dosing interval, thereby raising the minimum ara-CTP level in leukemic cells between doses. This initial attempt at pharmacologic direction of chemotherapy was successful in elevating minimum ara-CTP levels but did not produce an increase in response rate, probably because the total duration of ara-CTP exposure was decreased when the dose intervals were shortened. Currently we are engaged in a new approach based on the knowledge accumulated over the past three years. Patients receive a test ara-C dose from which data on ara-CTP cellular metabolism is derived, followed by a CI of ara-C at a dose calculated individually for each patient. Preliminary results of this approach thus far indicate an increased response rate and a different spectrum of toxicity than that observed with intermittent dose ara-C. Further clinical trials will determine the true effectiveness of this approach.
Asunto(s)
Trifosfato de Arabinofuranosil Citosina/sangre , Arabinonucleotidos/sangre , Citarabina/uso terapéutico , Leucemia/tratamiento farmacológico , Citarabina/administración & dosificación , Citarabina/sangre , ADN/biosíntesis , Resistencia a Medicamentos , Humanos , Cinética , Leucemia/sangreRESUMEN
Cytosine arabinoside (ara-C) has been used in the treatment of leukemia, but its exact mechanism of cytotoxicity is not yet known. One of the proposed mechanisms for the effectiveness of this drug in treating leukemias suggests that a metabolite of ara-C, i.e., 2'-deoxycytidine 5'-triphosphate (araCTP), competes with cytosine arabinoside 5'-triphosphate (dCTP) for binding to DNA polymerase. The ratio of the drug metabolite to the endogenous nucleotide (araCTP/dCTP) may, therefore, be important in determining the effectiveness of ara-C therapy. This ratio may also play a role in drug resistance. Previously published methods have focused on either araCTP or dCTP, along with metabolites and analogues of one of these compounds. The methods presented here provide two simple, sensitive ways to measure dCTP and araCTP in the same biological sample.
Asunto(s)
Trifosfato de Arabinofuranosil Citosina/análisis , Arabinonucleotidos/análisis , Citarabina/metabolismo , Nucleótidos de Desoxicitosina/análisis , Trifosfato de Arabinofuranosil Citosina/sangre , Médula Ósea/análisis , Niño , Cromatografía Líquida de Alta Presión/métodos , Citarabina/uso terapéutico , Nucleótidos de Desoxicitosina/sangre , Humanos , Leucemia/tratamiento farmacológico , Espectrofotometría UltravioletaRESUMEN
A rapid, non-radioactive method to quantitate therapeutically realistic levels of 1-beta-D-arabinofuranosylcytosine (Ara-C) and its metabolites would be useful both in the clinic, for monitoring drug levels, and in the laboratory for correlating drug levels with cellular and molecular perturbations. Liquid chromatographic analysis of arabinose-nucleoside analogs in biological samples is complicated by the presence of interfering nucleosides and nucleotides. We report the development of two analytic procedures to measure Ara-C and metabolite levels in biological samples. One method uses a quaternary ammonium type anion-exchange resin to achieve isocratic separation in less than one hour. The second method utilizes a boronate-derivatized polyacrylamide column which binds cis-diols to selectively retain cytosine and uridine, while arabinose compounds are eluted with recovery approaching 100%. The eluted compounds are then easily quantitated on a reversed-phase C18 column. The sensitivity of both procedures was sufficient to obtain pharmacokinetic data on Ara-C and uracil-arabinose levels in serum and urine and on Ara-C triphosphate levels in tumor cells.